Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shield Therapeutics ( (GB:STX) ) just unveiled an announcement.
Shield Therapeutics has announced that its total issued share capital consists of 1,061,802,812 ordinary shares, each with equal voting rights, as per FCA’s Disclosure and Transparency Rule. The company’s flagship product, ACCRUFeR®, is the first FDA-approved oral iron treatment for iron deficiency, representing a significant market opportunity and addressing unmet medical needs.
The most recent analyst rating on (GB:STX) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily influenced by the company’s robust technical performance, indicating strong market momentum. However, significant financial weaknesses, including negative profitability and cash flow issues, weigh heavily on the score. Valuation concerns due to a negative P/E ratio and lack of dividend yield further impact the stock’s attractiveness.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage pharmaceutical company specializing in iron deficiency treatment. Their primary product, ACCRUFeR®/FeRACCRU® (ferric maltol), is an innovative oral therapy for iron deficiency and iron deficiency anemia, with a significant market presence in the U.S. and licensing agreements in multiple regions worldwide.
Average Trading Volume: 4,277,911
Technical Sentiment Signal: Buy
Current Market Cap: £74.85M
See more data about STX stock on TipRanks’ Stock Analysis page.